Vaxxas Appoints David Hoey as Company’s First CEO

You may also like

19 April 2016

Icon Group signs up Charm Health to support cancer care

12 January 2021

Clinical Genomics Announces Nationwide Expansion of Patient Access to COLVERA®

07 October 2021

Blade Therapeutics Announces Publication of Preclinical Evidence Supporting Neuroprotective Effects of Proprietary Calpain Inhibitor in a Rare Inherited Neurodegenerative Disease

27 May 2017

OneVentures makes first investment for the Biomedical Translation Fund

05 February 2018

OneVentures’ Investee Smart Sparrow Secures Strategic Investment from Global Education Leader

18 July 2016

DoseMe partners with Charm Health to improve management of high risk oncology medicines and deliver “precision medicine” to Australian cancer patients

View All

Ventured. Gained.

Subscribe to our Newsletter for the latest updates from 1V.

decor decor decor
decor decor decor decor decor